| Oct 31 |
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
|
| Oct 30 |
Dogwood Therapeutics regains compliance with Nasdaq's minimum bid price rule
|
| Oct 30 |
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
| Oct 14 |
DWTX: Virios Therapeutics Becomes Dogwood Therapeutics; Focus on Chemotherapy-Induced Neuropathic Pain…
|
| Oct 8 |
Virios Therapeutics Transforms into Dogwood Therapeutics
|
| Oct 7 |
Virios Therapeutics Enters Into Definitive Merger Agreement With Wex Pharmaceuticals
|
| Oct 7 |
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics
|
| Oct 7 |
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
|
| Aug 13 |
VIRI: Enrollment Complete in Phase 2a Long COVID Trial; Results Expected in October 2024…
|
| Aug 9 |
Virios Therapeutics reports Q2 results
|
